ClinicalTrials.gg
CompletedNCT01578707RESONATE™Updated Dec 18, 2019Results posted

A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

A Phase 3 interventional study of ofatumumab and ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by Pharmacyclics LLC.. Completed at 76 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-18.

Primary conditionLeukemia, Lymphocytic, Chronic, B-CellRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Lymphocytic, Chronic, B-Cell
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Leukemia, Lymphocytic, Chronic, B-Cell.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
391
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 8 open to participants now, 28 under way, 4 of them phase 3. ibrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
7th of 83
391 · median 44
Started
2012
with 6 others
Phase 3
14 of 83
none open now
Registered
7th of 83
by date
Lead sponsor
10 of 83
Pharmacyclics LLC.

Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 7th largest by enrollment, is one of 7 that started in 2012, is one of 14 in phase 3, and was the 7th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,038 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

8 of the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate whether treatment with ibrutinib as a monotherapy results in a clinically significant improvement in progression free survival (PFS) as compared to treatment with ofatumumab in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Read the detailed description

Study PCYC-1112-CA is a randomized, multicenter, open-label, phase 3 study of the Bruton's Tyrosine Kinase (BTK) inhibitor Ibrutinib (PCI-32765) versus Ofatumumab in patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Patients randomized to the ofatumumab arm may be considered to receive next subsequent therapy with ibrutinib.

03

Conditions studied

  • Relapsed or Refractory Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Keywords

  • Chronic
  • SLL
  • CLL
  • Ofatumumab
  • ibrutinib
  • RESONATE
  • Phase III
  • Leukemia
  • Lymphoma
04

In context

Leukemia, Lymphocytic, Chronic, B-Cell Reclassified

2,038 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

This study's enrollment of 391 is above the median of 39 across 1,605 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Lead sponsor

Pharmacyclics LLC. is the lead sponsor of 54 studies on the registry; none are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.

First submitted before Pharmacyclics LLC. became part of AbbVie.

Compared within Leukemia, Lymphocytic, Chronic, B-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • performance status of 0-1.
  • Diagnosis of CLL or SLL that meets IWCLL 2008 criteria.
  • Active disease meeting at least 1 of the IWCLL 2008 criteria for requiring treatment.
  • Must have received at least one prior therapy for CLL/SLL.
  • Considered not appropriate for treatment or retreatment with purine analog based therapy.
  • Measurable nodal disease by CT.
  • Patients must be able to receive outpatient treatment and laboratory monitoring at the institution that administers study drug for the entire study.

Exclusion criteria

Exclusion Criteria:

  • Known CNS lymphoma or leukemia.
  • No documentation of cytogenetic and/or FISH in patient records prior to first dose of study drug.
  • Any history of Richter's transformation or prolymphocytic leukemia.
  • Uncontrolled Hemolytic Anemia (AIHA) or idiopathic thrombocytopenia purpura (ITP).
  • Prior exposure to ofatumumab or to ibrutinib.
  • Prior transplant within 6 months prior to first dose of study drug.
  • Prior allogeneic stem cell transplant within 6 months or with any evidence of active or requirement for within 28 days prior to first dose of study drug.
  • History of prior , with the exception of certain skin cancers and malignancies treated with curative intent and with no evidence of active disease for more than 3 years.
  • Serologic status reflecting active or C infection.
  • Unable to swallow capsules or disease significantly affecting gastrointestinal function.
  • Uncontrolled active systemic fungal, bacterial, viral, or other infection.
  • History of stroke or intracranial hemorrhage within 6 months prior to the first dose of study drug.
  • Requires anticoagulation with warfarin.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
391 participants (actual)

Study arms

  • Active comparator
    Ofatumumab (Arm A)

    An anti-CD20 monoclonal antibody

    Drug: ofatumumab

  • Experimental
    ibrutinib (Arm B)

    A Bruton Tyrosine Kinase Inhibitor

    Drug: ibrutinib

Interventions

  • The ofatumumab (IV) dosage and schedule is 12 doses administered over 24 weeks or until disease progression, unacceptable toxicity. Week 1: 300 mg initial dose Week 2 through 8: 2,000 mg (once weekly) Week 12, 16, 20 and 24: 2,000 mg (every 4 weeks)

  • ibrutinib 420 mg (3 x 140-mg capsules) will be administered orally once daily until disease progression or unacceptable toxicity

07

What researchers measure

Primary outcomes

  1. PFS (Progression Free Survival) by Independent Review Committee (IRC), Limited to the Time of Primary Analysis 06 November 2013

    The primary objective of this study was to evaluate the efficacy of ibrutinib compared to ofatumumab based on independent review committee (IRC) assessment of progression-free survival (PFS) according to 2008 IWCLL guidelines.

    Time frame: Analysis was conducted after observing approximately 117 PFS events, which occurred about 18 months after the first subject was enrolled.

Secondary outcomes

  1. Overall Response Rate (ORR) by Independent Review Committee (IRC)

    Overall Response Rate per the IWCLL 2008 criteria as assessed by IRC, limited to the time of primary analysis 06 November 2013

    Time frame: About 18 months after the first subject was enrolled

  2. OS (Overall Survival)

    OS analysis was conducted at the time of study closure, with no adjustment for crossover from the ofatumumab arm to the ibrutinib arm

    Time frame: OS analysis was conducted at the time of study closure, including up to 6 years of study follow-up

  3. Rate of Sustained Hemoglobin and Platelet Improvement

    Proportion of subjects with hemoglobin (HgB) increase \>=20 g/L and platelet (PLT) increase \>=50% over baseline continuously for \>=56 days without blood transfusions or growth factors.

    Time frame: From study initiation to study closure, including up to 6 years of study follow-up

Other outcomes

  1. Progression Free Survival (PFS) by Investigator With up to 6 Years of Study Follow-up

    Long-Term Progression Free Survival as assessed by the investigator with up to 6 years of study follow-up

    Time frame: From study initiation to study closure, including up to 6 years of study follow-up

  2. Overall Response Rate (ORR) by Investigator

    Overall response per the IWCLL 2008 criteria as assessed by Investigator with up to 6 years of study follow-up

    Time frame: From study initiation to study closure, including up to 6 years of study follow-up

08

Results

Posted Oct 12, 2015

Participant flow

Participant flow — Overall Study
MilestoneOfatumumab (Arm A)Ibrutinib (Arm B)
Started196195
Completed196195
Not completed00

Outcome measures

PrimaryPFS (Progression Free Survival) by Independent Review Committee (IRC), Limited to the Time of Primary Analysis 06 November 2013

The primary objective of this study was to evaluate the efficacy of ibrutinib compared to ofatumumab based on independent review committee (IRC) assessment of progression-free survival (PFS) according to 2008 IWCLL guidelines.

Time frame:
Analysis was conducted after observing approximately 117 PFS events, which occurred about 18 months after the first subject was enrolled.
Reported as:
Median · months
PFS (Progression Free Survival) by Independent Review Committee (IRC), Limited to the Time of Primary Analysis 06 November 2013
monthsOfatumumab (Arm A)Ibrutinib (Arm B)
PFS (Progression Free Survival) by Independent Review Committee (IRC), Limited to the Time of Primary Analysis 06 November 20138.1 (7.2 to 8.3)NA (NA to NA)
Statistical analysis
  • Ofatumumab (Arm A) · Log Rank · p = <0.0001
SecondaryOverall Response Rate (ORR) by Independent Review Committee (IRC)

Overall Response Rate per the IWCLL 2008 criteria as assessed by IRC, limited to the time of primary analysis 06 November 2013

Time frame:
About 18 months after the first subject was enrolled
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) by Independent Review Committee (IRC)
percentage of participantsOfatumumab (Arm A)Ibrutinib (Arm B)
Overall Response Rate (ORR) by Independent Review Committee (IRC)4.142.6
Statistical analysis
  • Ofatumumab (Arm A) · Fisher Exact · p = <.0001
SecondaryOS (Overall Survival)

OS analysis was conducted at the time of study closure, with no adjustment for crossover from the ofatumumab arm to the ibrutinib arm

Time frame:
OS analysis was conducted at the time of study closure, including up to 6 years of study follow-up
Reported as:
Median · months
OS (Overall Survival)
monthsOfatumumab (Arm A)Ibrutinib (Arm B)
OS (Overall Survival)65.1 (50.6 to NA)67.7 (61.0 to NA)
Statistical analysis
  • Ofatumumab (Arm A) · Log Rank · p = 0.1653
SecondaryRate of Sustained Hemoglobin and Platelet Improvement

Proportion of subjects with hemoglobin (HgB) increase \>=20 g/L and platelet (PLT) increase \>=50% over baseline continuously for \>=56 days without blood transfusions or growth factors.

Time frame:
From study initiation to study closure, including up to 6 years of study follow-up
Reported as:
Number · percentage of participants
Rate of Sustained Hemoglobin and Platelet Improvement
percentage of participantsOfatumumab (Arm A)Ibrutinib (Arm B)
Hgb Improvement in patient with baseline anemia32.669.7
Platelet improvement in baseline thrombocytopenia9.478.4
Other pre-specifiedProgression Free Survival (PFS) by Investigator With up to 6 Years of Study Follow-up

Long-Term Progression Free Survival as assessed by the investigator with up to 6 years of study follow-up

Time frame:
From study initiation to study closure, including up to 6 years of study follow-up
Reported as:
Median · months
Progression Free Survival (PFS) by Investigator With up to 6 Years of Study Follow-up
monthsOfatumumab (Arm A)Ibrutinib (Arm B)
Progression Free Survival (PFS) by Investigator With up to 6 Years of Study Follow-up8.1 (7.79 to 8.25)44.1 (38.47 to 56.18)
Other pre-specifiedOverall Response Rate (ORR) by Investigator

Overall response per the IWCLL 2008 criteria as assessed by Investigator with up to 6 years of study follow-up

Time frame:
From study initiation to study closure, including up to 6 years of study follow-up
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) by Investigator
percentage of participantsOfatumumab (Arm A)Ibrutinib (Arm B)
Overall Response Rate (ORR) by Investigator22.487.7

Adverse events

Collected over From first dose of study drug to within 30 days of last dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ofatumumab (Arm A)16/191 (8.4%)59/191 (30.9%)185/191 (96.9%)
Ibrutinib (Arm B)24/195 (12.3%)141/195 (72.3%)194/195 (99.5%)
Most frequent serious events
Showing 10 of 249
Most frequent serious events
EventOfatumumab (Arm A)Ibrutinib (Arm B)
PneumoniaInfections and infestations12/19142/195
PyrexiaGeneral disorders4/19115/195
Atrial FibrillationCardiac disorders1/19111/195
Urinary Tract InfectionInfections and infestations0/1919/195
CellulitisInfections and infestations1/1918/195
SepsisInfections and infestations2/1918/195
Febrile NeutropeniaBlood and lymphatic system disorders4/1917/195
Lung InfectionInfections and infestations0/1917/195
DiarrhoeaGastrointestinal disorders1/1916/195
Subdural HaematomaInjury, poisoning and procedural complications0/1916/195
Most frequent other events
Showing 10 of 104
Most frequent other events
EventOfatumumab (Arm A)Ibrutinib (Arm B)
DiarrhoeaGastrointestinal disorders33/191120/195
FatigueGeneral disorders57/19182/195
CoughRespiratory, thoracic and mediastinal disorders43/19178/195
Upper Respiratory Tract InfectionInfections and infestations17/19177/195
NauseaGastrointestinal disorders38/19169/195
PyrexiaGeneral disorders27/19166/195
Infusion Related ReactionInjury, poisoning and procedural complications64/1910/195
AnaemiaBlood and lymphatic system disorders32/19162/195
NeutropeniaBlood and lymphatic system disorders25/19160/195
ArthralgiaMusculoskeletal and connective tissue disorders14/19153/195

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Ofatumumab (Arm A)Ibrutinib (Arm B)Total
<=18 years000
Between 18 and 65 years7577152
>=65 years121118239
Age, Continuous
Age, Continuous(years)Ofatumumab (Arm A)Ibrutinib (Arm B)Total
Mean66.8 ± 8.8866.1 ± 10.1566.5 ± 9.53
Sex: Female, Male
Sex: Female, Male(Participants)Ofatumumab (Arm A)Ibrutinib (Arm B)Total
Female5966125
Male137129266
09

Study locations

76 sites
  • Site #408
    La Jolla, California 92093-0698, United States
  • Site #377
    Los Angeles, California 90095, United States
  • Site #403
    Santa Maria, California 93454, United States
  • Site #038
    Stanford, California 94035, United States
  • Site #411
    Norwalk, Connecticut 06856, United States
  • Site #107
    Marietta, Georgia 30060, United States
  • Site # 379
    Evansville, Indiana 47713, United States
  • Site # 390
    Boston, Massachusetts 02114, United States
  • Site # 391
    Boston, Massachusetts 02115, United States
  • Site # 349
    Boston, Massachusetts 02215, United States
  • Site # 130
    Detroit, Michigan 48201, United States
  • Site # 406
    Rochester, Minnesota 55901, United States
  • Site # 059
    New Brunswick, New Jersey 08903, United States
  • Site # 350
    New Hyde Park, New York 11042, United States
  • Site # 200
    New York, New York 10065, United States
  • Site # 127
    Rochester, New York 14642-0001, United States
  • Site # 197
    Cincinnati, Ohio 45291, United States
  • Site # 217
    Columbus, Ohio 43210, United States
  • Site # 402
    Philadelphia, Pennsylvania 19104, United States
  • Site # 396
    Greenville, South Carolina 29601, United States
  • Site # 410
    Nashville, Tennessee 37232-5505, United States
  • Site # 032
    Houston, Texas 77030, United States
  • Site # 381
    Laredo, Texas 78041, United States
  • Site # 210
    Charlottesville, Virginia 22908, United States
  • Site # 404
    Seattle, Washington 98109, United States
  • Site # 500
    St. Leonards, New South Wales 2065, Australia
  • Site # 503
    Brisbane, Queensland 4102, Australia
  • Site # 199
    East Melbourne, Victoria 3002, Australia
  • Site # 501
    Fitzroy, Victoria 3109, Australia
  • Site # 502
    Nedlands, Western Australia 6009, Australia
  • Site # 509
    Graz, 8036, Austria
  • Site # 508
    Linz, 4010, Austria
  • Site # 504
    Salzburg, 5020, Austria
  • Site # 505
    Vienna, A-1090, Austria
  • Site # 506
    Wein, 1160, Austria
  • Site # 507
    Wels, A-4600, Austria
  • Site # 393
    Antwerpen, 2060, Belgium
  • Site # 519
    Argenteuil, 95107, France
  • Site # 511
    Bobigny, 93009, France
  • Site # 515
    Bordeaux, 33076, France
  • Site # 516
    Caen, 14033, France
  • Site # 513
    Clermont Ferrand, 63100, France
  • Site # 510
    Marseille, 13273, France
  • Site # 520
    Nantes, 44000, France
  • Site # 518
    Rennes, 35033, France
  • Site # 517
    Vandœuvre-lès-Nancy, 54511, France
  • Site # 570
    Dublin, 8, Ireland
  • Site # 528
    Dublin, 9, Ireland
  • Site # 096
    Galway, Ireland
  • Site # 522
    Milano, 20089, Italy
  • Site # 523
    Milano, 20132, Italy
  • Site # 526
    Milano, 20162, Italy
  • Site # 524
    Modena, 41124, Italy
  • Site # 527
    Padova, 35128, Italy
  • Site # 529
    Gdansk, 80-952, Poland
  • Site # 531
    Lodz, 93-510, Poland
  • Site # 535
    Barcelona, 08025, Spain
  • Site # 534
    Barcelona, 08035, Spain
  • Site # 533
    Barcelona, 08036, Spain
  • Site # 539
    Coruna, 15006A, Spain
  • Site # 540
    Madrid, 28033, Spain
  • Site # 537
    Madrid, 28050, Spain
  • Site # 536
    Madrid, 28222, Spain
  • Site # 538
    Pamplona, 31008, Spain
  • Site # 549
    Colchester, Essex CO4 5JL, United Kingdom
  • Site # 543
    Sutton, Surrey SM2 5PT, United Kingdom
  • Site # 551
    Bournemouth, BH7 7DW, United Kingdom
  • Site # 553
    Canterbury, CT1 3NG, United Kingdom
  • Site # 546
    Cardiff, CF14 4XW, United Kingdom
  • Site # 554
    Headington, OX3 7LJ, United Kingdom
  • Site # 550
    Leeds, LS9 7TF, United Kingdom
  • Site # 552
    Liverpool, L7 8XP, United Kingdom
  • Site # 544
    London, SE5 9RS, United Kingdom
  • Site # 548
    Nottingham, NG5 1PB, United Kingdom
  • Site # 545
    Southampton, SO16 6YD, United Kingdom
  • Site # 541
    Withington, M20 4BX, United Kingdom
10

References and documents

Publications

  • Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019 Dec;94(12):1353-1363. doi: 10.1002/ajh.25638. Epub 2019 Oct 13. PubMed 31512258 ↗
  • Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA, O'Dwyer M, Ghia P, Valentino R, Chang S, Dean JP, James DF, O'Brien SM. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019 Jun 25;3(12):1799-1807. doi: 10.1182/bloodadvances.2018028761. PubMed 31196847 ↗
  • Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Thornton P, Moreno C, Montillo M, Pagel JM, Burger JA, Woyach JA, Dai S, Vezan R, James DF, Brown JR. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019 May 9;133(19):2031-2042. doi: 10.1182/blood-2018-08-870238. Epub 2019 Mar 6. PubMed 30842083 ↗
  • O'Brien SM, Jaglowski S, Byrd JC, Bannerji R, Blum KA, Fox CP, Furman RR, Hillmen P, Kipps TJ, Montillo M, Sharman J, Suzuki S, James DF, Chu AD, Coutre SE. Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol. 2018 May 1;4(5):712-716. doi: 10.1001/jamaoncol.2017.5604. PubMed 29470582 ↗
  • Brown JR, Moslehi J, O'Brien S, Ghia P, Hillmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Kipps TJ, Coutre S, Dilhuydy MS, Cramer P, Tedeschi A, Jaeger U, Dreyling M, Byrd JC, Howes A, Todd M, Vermeulen J, James DF, Clow F, Styles L, Valentino R, Wildgust M, Mahler M, Burger JA. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017 Oct;102(10):1796-1805. doi: 10.3324/haematol.2017.171041. Epub 2017 Jul 27. PubMed 28751558 ↗
  • Barr PM, Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Mulligan SP, Jaeger U, Furman RR, Cymbalista F, Montillo M, Dearden C, Robak T, Moreno C, Pagel JM, Burger JA, Suzuki S, Sukbuntherng J, Cole G, James DF, Byrd JC. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017 May 11;129(19):2612-2615. doi: 10.1182/blood-2016-12-737346. Epub 2017 Apr 3. PubMed 28373262 ↗
  • Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncol. 2015 Apr;1(1):80-7. doi: 10.1001/jamaoncol.2014.218. PubMed 26182309 ↗
  • Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P; RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014 Jul 17;371(3):213-23. doi: 10.1056/NEJMoa1400376. Epub 2014 May 31. PubMed 24881631 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2012 to primary completion in Nov 2013, 17 months.

Results were first posted in Oct 2015, 1 year 11 months after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 17 months is below that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2012
First posted
Apr 17, 2012
StartActual
Jun 2012
Primary completionActual
Nov 2013
CompletionActual
Oct 25, 2018
Results first posted
Oct 12, 2015
Last update
Dec 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01578707
Lead sponsor
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Apr 17, 2012
Start date
Jun 2012
Primary completion
Nov 2013
Completion
Oct 25, 2018
Results posted
Oct 12, 2015
Last update
Dec 18, 2019

Study contacts

Anita Szoke, MD
study director · Pharmacyclics LLC.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion